GlobeNewswire Inc.Jun 10, 1:00 PM ET▲ Positive
Reported initial safety and efficacy data from Phase I study of ADI-001 (anti-CD20) in October 2025, demonstrating clinical progress.
Adicet Bio news
$6.83+7.56%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Adicet Bio
No recent articles focused on Adicet Bio.
Also mentions ACET
Articles that tag ACET but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology